Register | Log in | FAQ      [?] 

Tag clinical_trial [108 articles]

Recent papers classified by the tag clinical_trial.
  • Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials
    Biostat, Vol. 2, No. 2. (1 June 2001), pp. 203-215.
    by Yong Lin, Weichung J Shih
    posted to algorithm_based_design clinical_trial phase_i by wbrady5 on 2008-01-09 15:11:16 as read
  • Accelerated titration designs for phase I clinical trials in oncology
    J. Natl. Cancer Inst., Vol. 89, No. 15. (6 August 1997), pp. 1138-1147.
    by R Simon, B Freidlin, L Rubinstein, SG Arbuck, J Collins, MC Christian
    posted to ab_design clinical_trial phase_i by wbrady5 on 2008-01-07 19:46:36 as read
  • Are Phase 2 screening trials in oncology obsolete?
    Statistics in Medicine, Vol. 27, No. 4. (2008), pp. 556-567.
    by Eric Holmgren
    posted to clinical_trial phase_ii phase_ii_screening_trial by wbrady5 on 2008-01-10 15:25:05 as ****
  • A three-outcome design for randomized comparative phase II clinical trials
    Statistics in Medicine, Vol. 26, No. 19. (2007), pp. 3525-3534.
    by Shengyan Hong, Yanping Wang
    posted to clinical_trial phase_ii three_outcome_design by wbrady5 on 2008-03-04 14:57:28 as **
  • Recent Developments in Adaptive Designs for Phase I/II Dose-Finding Studies
    Journal of Biopharmaceutical Statistics, Vol. 17, No. 6. (2007), pp. 1071-1083.
    by Sarah Zohar, Sylvie Chevret
    posted to adaptive clinical_trial dose_finding by wbrady5 on 2008-01-26 16:28:24 as **
  • A Bayesian Approach to Jointly Modeling Toxicity and Biomarker Expression in a Phase I/II Dose-Finding Trial
    Biometrics, Vol. 61, No. 2. (June 2005), pp. 343-354.
    by B Nebiyou, Yu Shen
    posted to bayesian biomarker clinical_trial phase_i phase_ii toxicity by wbrady5 on 2008-01-04 21:46:56 as **
  • Selection Designs for Pilot Studies Based on Survival
    Biometrics, Vol. 49, No. 2. (1993), pp. 391-398.
    by PY Liu, Steve Dahlberg, John Crowley
    posted to clinical_trial selection_design survival by wbrady5 on 2008-03-06 14:39:02 as **
  • Sequential Designs for Phase I Clinical Trials with Late-Onset Toxicities
    Biometrics, Vol. 56, No. 4. (2000), pp. 1177-1182.
    by Ying K Cheung, Rick Chappell
    posted to clinical_trial continual_reassessment_method phase_i by wbrady5 on 2008-01-04 21:45:12 as read
  • Innovative Approaches in Drug Development
    Journal of Biopharmaceutical Statistics, Vol. 17, No. 5. (September 2007), pp. 775-789.
    by Chang, Mark, Kenley, Susan, Bull, Jonca, Chiu, Yuan-Yuan, Wang, Wenjin, Wakeford, Charles, Mccarthy, Katherine
    posted to clinical_trial by wbrady5 on 2008-01-26 16:33:39 as ****
  • Can external and subjective information ever be used to reduce the size of randomised controlled trials?
    Contemporary Clinical Trials, Vol. 29, No. 2. (March 2008), pp. 211-219.
    by Say-Beng Tan, Joseph Wee, Hwee-Bee Wong, David Machin
    posted to bayesian clinical_trial rare_tumors by wbrady5 on 2008-03-05 16:32:47 as ** along with 1 person jyuh
  • Retrospective Analysis of Sequential Dose-Finding Designs
    Biometrics, Vol. 61, No. 3. (2005), pp. 749-756.
    by John O'Quigley
    posted to ab_design clinical_trial continual_reassessment_method phase_i by wbrady5 on 2008-01-04 22:01:02 as **
  • Dose-Finding with Two Agents in Phase I Oncology Trials
    Biometrics, Vol. 59, No. 3. (2003), pp. 487-496.
    by Peter F Thall, Randall E Millikan, Peter Mueller, Sang J Lee
    posted to bayesian clinical_trial combination_therapy phase_i toxicity by wbrady5 on 2008-01-04 21:31:11 as read
  • Two-Stage Selection and Testing Designs for Comparative Clinical Trials
    Biometrika, Vol. 75, No. 2. (1988), pp. 303-310.
    by Peter F Thall, Richard Simon, Susan S Ellenberg
    posted to clinical_trial selection_design by wbrady5 on 2008-03-06 14:16:33 as **
  • Adaptive Dose Selection Using Efficacy-Toxicity Trade-Offs: Illustrations and Practical Considerations
    Journal of Biopharmaceutical Statistics, Vol. 16, No. 5. (2006), pp. 623-638.
    by Peter F Thall, John D Cook, Elihu H Estey
    posted to bayesian bivariate clinical_trial continual_reassessment_method phase_i by wbrady5 on 2008-01-02 22:12:27 as **
  • Sample Sizes Based on Exact Unconditional Tests for Phase II Clinical Trials with Historical Controls
    Journal of Biopharmaceutical Statistics, Vol. 14, No. 1. (2004), pp. 189-200.
    by Myron N Chang, Jonathan J Shuster, James L Kepner
    posted to binomial clinical_trial historical_control phase_ii by wbrady5 on 2008-03-12 14:25:42 as read
  • Optimal designs for estimating the most successful dose
    Statistics in Medicine, Vol. 25, No. 24. (2006), pp. 4311-4320.
    by Sarah Zohar, John O'Quigley
    posted to bivariate clinical_trial efficacy optimal_design toxicity by wbrady5 on 2008-01-02 22:32:40 as **
  • Bayesian Optimal Designs for Phase I Clinical Trials
    Biometrics, Vol. 59, No. 3. (2003), pp. 591-600.
    by Linda M Haines, Inna Perevozskaya, William F Rosenberger
    posted to bayesian clinical_trial optimal_design phase_i by wbrady5 on 2008-01-04 21:33:54 as **
  • Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design
    J Clin Oncol, Vol. 26, No. 2. (10 January 2008), pp. 190-195.
    by Jeffrey M Skolnik, Jeffrey S Barrett, Bhuvana Jayaraman, Dimple Patel, Peter C Adamson
    posted to ab_design clinical_trial pediatric phase_i by wbrady5 on 2008-01-09 22:29:45 as **
  • A New Dose-Finding Design for Bivariate Outcomes
    Biometrics, Vol. 59, No. 4. (2003), pp. 1001-1007.
    by Anastasia Ivanova
    posted to bivariate clinical_trial phase_i by wbrady5 on 2008-01-04 22:08:03 as **
  • Optimal two-stage designs for phase II clinical trials.
    Control Clin Trials, Vol. 10, No. 1. (March 1989), pp. 1-10.
    by R Simon
    posted to clinical_trial optimal_design phase_ii by wbrady5 on 2008-01-11 15:38:06 as read
  • A comment on futility monitoring
    Controlled Clinical Trials, Vol. 23, No. 4. (August 2002), pp. 355-366.
    by Boris Freidlin, Edward L Korn
    posted to clinical_trial conditional_power futility monitoring monitoring_guidelines sequential stochastic_curtailment by wbrady5 on 2008-01-11 19:23:45 as **
  • Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?
    J Clin Oncol, Vol. 19, No. 1. (1 January 2001), pp. 265-272.
    by Edward L Korn, Susan G Arbuck, James M Pluda, Richard Simon, Richard S Kaplan, Michaele C Christian
    posted to clinical_trial cytostatic phase_i phase_ii phase_iii by wbrady5 on 2008-02-22 15:01:50 as **
  • Conditional power calculations for clinical trials with historical controls
    Statistics in Medicine, Vol. 25, No. 17. (2006), pp. 2922-2931.
    by Edward L Korn, Boris Freidlin
    posted to clinical_trial conditional_power historical_control phase_ii predictive_power sample_size_calculation by wbrady5 on 2008-01-11 18:50:40 as **
  • Simulation as a design tool for phase I/II clinical trials: An example from bone marrow transplantation
    Controlled Clinical Trials, Vol. 15, No. 6. (December 1994), pp. 450-462.
    by Ted A Gooley, Paul J Martin, Lloyd D Fisher, Mary Pettinger
    posted to clinical_trial phase_i phase_ii simulation by wbrady5 on 2008-01-07 13:58:52 as **
  • An optimization algorithm for designing phase I cancer clinical trials
    Contemporary Clinical Trials, Vol. 29, No. 2. (March 2008), pp. 102-108.
    by Hui Jiang, Yifan Liu, Zheng Su
    posted to algorithm_based_design clinical_trial phase_i by wbrady5 on 2008-03-05 16:30:06 as **
  • Randomized phase II trials with a prospective control.
    Stat Med (15 June 2007)
    by Sin-Ho H Jung
    posted to clinical_trial futility optimal_design phase_ii randomization two-stage by wbrady5 on 2008-03-07 19:34:19 as **
  • Dose Finding Using the Biased Coin Up-and-Down Design and Isotonic Regression
    Biometrics, Vol. 58, No. 1. (2002), pp. 171-177.
    by Mario Stylianou, Nancy Flournoy
    posted to clinical_trial dose_finding up_and_down_design by wbrady5 on 2008-01-04 22:10:50 as **
  • A Parallel Phase III Clinical Trial Design for Combination Therapies
    Biometrics, Vol. 63, No. 2. (June 2007), pp. 429-436.
    by Huang, Xuelin, Biswas, Swati, Oki, Yasuhiro, Issa, Jean-Pierre, Berry, A Donald
    posted to bayesian bivariate clinical_trial combination_therapy phase_i phase_ii toxicity by wbrady5 on 2008-01-04 21:59:15 as **
  • Bayesian Dose-Finding in Phase III Clinical Trials Using Toxicity and Efficacy Odds Ratios
    Biometrics, Vol. 62, No. 3. (September 2006), pp. 777-787.
    by Yin, Guosheng, Li, Yisheng, Ji, Yuan
    posted to adaptive bayesian bivariate clinical_trial phase_i by wbrady5 on 2008-01-04 21:51:07 as **
  • 3 + 3 != (Rolling) 6
    J Clin Oncol, Vol. 26, No. 2. (10 January 2008), pp. 170-171.
    by Christine Hartford, Samuel L Volchenboum, Susan L Cohn
    posted to clinical_trial editorial pediatric phase_i by wbrady5 on 2008-01-09 22:30:31 as **
  • Phase I Studies of Chemotherapeutic Agents in Cancer Patients: A Review of the Designs
    Journal of Biopharmaceutical Statistics, Vol. 16, No. 5. (2006), pp. 579-604.
    by Douglas M Potter
    posted to clinical_trial phase_i review by wbrady5 on 2007-12-21 19:46:24 as read
  • Comments on ?Bayesians in clinical trials: Asleep at the switch? by Lemuel A. Moyé, <I>Statistics in Medicine</I>
    Statistics in Medicine, Vol. 27, No. 4. (2008), pp. 483-487.
    by Kathryn Chaloner
    posted to bayesian clinical_trial by wbrady5 on 2008-01-10 15:23:08 as read
  • Data Monitoring Committees and Interim Monitoring Guidelines
    Controlled Clinical Trials, Vol. 20, No. 5. (October 1999), pp. 395-407.
    by Boris Freidlin, Edward L Korn, Stephen L George
    posted to bayesian clinical_trial interim_analysis sequential stochastic_curtailment by wbrady5 on 2008-01-16 15:34:07 as **
  • Practical Bayesian Guidelines for Phase IIB Clinical Trials
    Biometrics, Vol. 50, No. 2. (1994), pp. 337-349.
    by Peter F Thall, Richard Simon
    posted to bayesian clinical_trial phase_ii by wbrady5 on 2008-01-10 18:23:33 as **
  • Bayesians in clinical trials: Asleep at the switch.
    Stat Med (15 June 2007)
    by Lemuel A A Moyé
    posted to bayesian clinical_trial by wbrady5 on 2008-01-10 15:15:06 as read along with 2 people jyuh Borelli
  • Stochastically curtailed tests in long–term clinical trials
    Sequential Analysis, Vol. 1, No. 3. (1982), pp. 207-219.
    by Gordon KK Lan, Richard Simon, Max Halperin
    posted to clinical_trial sequential stochastic_curtailment by wbrady5 on 2008-03-05 14:10:28 as **
  • A Three-Outcome Design for Phase II Clinical Trials
    Controlled Clinical Trials, Vol. 22, No. 2. (February 2001), pp. 117-125.
    by Daniel J Sargent, Victor Chan, Richard M Goldberg
    posted to clinical_trial phase_ii three_outcome_design by wbrady5 on 2008-03-04 15:00:13 as **
  • Designs for Single- or Multiple-Agent Phase I Trials
    Biometrics, Vol. 60, No. 3. (2004), pp. 661-669.
    by Mark R Conaway, Stephanie Dunbar, Shyamal D Peddada
    posted to clinical_trial combination_therapy phase_i toxicity by wbrady5 on 2008-01-04 21:35:23 as **
  • One-Sample Multiple Testing Procedure for Phase II Clinical Trials
    Biometrics, Vol. 38, No. 1. (1982), pp. 143-151.
    by Thomas R Fleming
    posted to clinical_trial multiple_testing phase_ii by wbrady5 on 2008-01-11 17:41:44 as **
  • The B-Value: A Tool for Monitoring Data
    Biometrics, Vol. 44, No. 2. (1988), pp. 579-585.
    by Gordon KK Lan, Janet Wittes
    posted to brownian b-value clinical_trial conditional_power interim_analysis motion stochastic_curtailment by wbrady5 on 2008-01-16 21:21:48 as **
  • Optimal phase I dose-escalation trial designs in oncology - A simulation study
    Statistics in Medicine, Vol. 9999, No. 9999. (2007), n/a.
    by Oke Gerke, Harald Siedentop
    posted to clinical_trial phase_i simulation by wbrady5 on 2008-01-26 00:22:32 as **
  • Rejoinder: The new adversary
    Statistics in Medicine, Vol. 27, No. 4. (2008), pp. 488-489.
    by Lemuel A Moyé
    posted to bayesian clinical_trial by wbrady5 on 2008-01-10 15:23:33 as **
  • Design and Analysis of Phase I Clinical Trials
    Biometrics, Vol. 45, No. 3. (1989), pp. 925-937.
    by Barry E Storer
    posted to clinical_trial phase_i by wbrady5 on 2008-01-17 22:28:02 as read
  • Science as experiment; science as observation
    Nat Clin Pract Rheum, Vol. 2, No. 6. (June 2006), pp. 286-287.
    by Eliza F Chakravarty, James F Fries
    posted to clinical_trial ebm epidemiology evidence evidence-based experiment observation rct by wandall on 2006-12-19 14:26:03 as **
  • A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression.
    Am J Psychiatry, Vol. 164, No. 8. (August 2007), pp. 1242-1249.
    by MA Frye, H Grunze, T Suppes, SL McElroy, PE Keck, J Walden, GS Leverich, LL Altshuler, S Nakelsky, S Hwang, J Mintz, RM Post
    posted to bipolar clinical_trial stimulant by pseudopharm on 2007-08-05 16:48:31 as ****
  • Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
    Nat Med (2 September 2007)
    by Sandeep T T Patil, Lu Zhang, Ferenc Martenyi, Stephen L L Lowe, Kimberley A A Jackson, Boris V V Andreev, Alla S S Avedisova, Leonid M M Bardenstein, Issak Y Y Gurovich, Margarita A A Morozova, Sergey N N Mosolov, Nikolai G G Neznanov, Alexander M M Reznik, Anatoly B B Smulevich, Vladimir A A Tochilov, Bryan G G Johnson, James A A Monn, Darryle D D Schoepp
    posted to clinical_trial neuroleptic schizophrenia by pseudopharm on 2007-09-04 20:55:26 as **** along with 2 people lenov trace018
  • Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial.
    Arch Gen Psychiatry, Vol. 64, No. 6. (June 2007), pp. 633-647.
    by RS Keefe, RM Bilder, SM Davis, PD Harvey, BW Palmer, JM Gold, HY Meltzer, MF Green, G Capuano, TS Stroup, JP McEvoy, MS Swartz, RA Rosenheck, DO Perkins, CE Davis, JK Hsiao, JA Lieberman
    posted to clinical_trial neuroleptic neuropsychology schizophrenia by pseudopharm on 2007-06-17 20:19:02 as read
  • Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression.
    N Engl J Med (28 March 2007)
    by Gary S S Sachs, Andrew A A Nierenberg, Joseph R R Calabrese, Lauren B B Marangell, Stephen R R Wisniewski, Laszlo Gyulai, Edward S S Friedman, Charles L L Bowden, Mark D D Fossey, Michael J J Ostacher, Terence A A Ketter, Jayendra Patel, Peter Hauser, Daniel Rapport, James M M Martinez, Michael H H Allen, David J J Miklowitz, Michael W W Otto, Ellen B B Dennehy, Michael E E Thase
    posted to anti_depressant bipolar clinical_trial mood_stabilizer by pseudopharm on 2007-03-30 22:32:41 as read
  • Randomized Trial of Weekly, Twice-Monthly, and Monthly Interpersonal Psychotherapy as Maintenance Treatment for Women With Recurrent Depression
    Am J Psychiatry, Vol. 164, No. 5. (1 May 2007), pp. 761-767.
    by Ellen Frank, David J Kupfer, Daniel J Buysse, Holly A Swartz, Paul A Pilkonis, Patricia R Houck, Paola Rucci, Danielle M Novick, Victoria J Grochocinski, Deborah M Stapf
    posted to clinical_trial therapy by pseudopharm on 2007-05-04 20:58:31 as read along with 1 person suizan
  • Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
    JAMA, Vol. 299, No. 2. (9 January 2008), pp. 185-193.
    by RR Wu, JP Zhao, H Jin, P Shao, MS Fang, XF Guo, YQ He, YJ Liu, JD Chen, LH Li
    posted to clinical_trial endocrine neuroleptic side_effect by pseudopharm on 2008-03-23 02:00:12 as read
    • Note: You may cite this page as: http://www.citeulike.org/tag/clinical_trial

    Result page: 1 2 3 Next RIS BibTeX
    CiteULike organises scholarly (or academic) papers or literature and provides bibliographic (which means it makes bibliographies) for universities and higher education establishments. It helps undergraduates and postgraduates. People studying for PhDs or in postdoctoral (postdoc) positions. The service is similar in scope to EndNote or RefWorks or any other reference manager like BibTeX, but it is a social bookmarking service for scientists and humanities researchers.